Zhaoke Ophthalmology’s Phase III Clinical Trial of Cyclosporine A (CsA) Ophthalmic Gel for Dry Eye Disease Meets Primary Endpoint

PR Newswire
August 19, 2021 — 12:43 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: China chinese guangdong Guangzhou healthcare Hillhouse Capital Group Hong Kong investment IPO manufacturing medicine OrbiMed patent pharmaceutical stock exchange

Related News:

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

November 8, 2024 — 17:45

LPS Launches NeuroNode: Empowering Advanced AI for Enterprises with On-Premises LLM

November 7, 2024 — 17:39

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

September 14, 2024 — 08:18

Desay Battery Highlights Advanced Energy Solutions at RE+ 2024

September 11, 2024 — 03:00

Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results

August 29, 2024 — 14:31

Telin and Indosat Ooredoo Hutchison Partner to Develop the Indonesia Cable System Express 2 (ICE System 2)

August 28, 2024 — 20:46

Hyundai Motor Group Companies’ Ratings Upgraded by Global Top Rating Agencies

August 26, 2024 — 17:24

2024 Belt and Road Journalists Forum to Be Held in Chongqing

August 25, 2024 — 17:50

WSPN Appoints Ex-Visa President John Partridge as Board Director

August 22, 2024 — 11:22

Franchising and Licensing Asia (FLAsia) 2024